JWK 001
Alternative Names: JWK-001Latest Information Update: 25 Aug 2026
At a glance
- Originator Chengdu Jinweike Biotechnology
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factors expression inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Wet age-related macular degeneration
- Phase I/II Diabetic macular oedema; Diabetic retinopathy
Most Recent Events
- 20 Aug 2026 Phase-II clinical trials in Wet age-related macular degeneration in China (Subretinal) (NCT07776522)
- 10 Oct 2025 Phase-I/II clinical trials in Diabetic macular oedema (Subretinal), prior to October 2025 (Chengdu-Jinweike-Biotechnology Pipeline, October 2025)
- 10 Sep 2024 Phase-I/II clinical trials in Diabetic retinopathy (Subretinal) prior to September 2024 (Chengdu-Jinweike-Biotechnology Pipeline, September 2024)